Revisiting the role of mitochondria in spinal muscular atrophy

Rachel James1 · Helena Chaytow1,2 · Leire M. Ledahawsky1 · Thomas H. Gillingwater1,2

Received: 1 December 2020 / Revised: 22 February 2021 / Accepted: 23 March 2021 / Published online: 5 April 2021 © The Author(s) 2021

Abstract
Spinal muscular atrophy (SMA) is an autosomal recessive motor neuron disease of variable clinical severity that is caused by mutations in the survival motor neuron 1 (SMN1) gene. Despite its name, SMN is a ubiquitous protein that functions within and outside the nervous system and has multiple cellular roles in transcription, translation, and proteostatic mechanisms. Encouragingly, several SMN-directed therapies have recently reached the clinic, albeit this has highlighted the increasing need to develop combinatorial therapies for SMA to achieve full clinical efficacy. As a subcellular site of dysfunction in SMA, mitochondria represents a relevant target for a combinatorial therapy. Accordingly, we will discuss our current understanding of mitochondrial dysfunction in SMA, highlighting mitochondrial-based pathways that offer further mechanistic insights into the involvement of mitochondria in SMA. This may ultimately facilitate translational development of targeted mitochondrial therapies for SMA. Due to clinical and mechanistic overlaps, such strategies may also benefit other motor neuron diseases and related neurodegenerative disorders.

Keywords Survival motor neuron · Mitochondrial dysfunction · Mitophagy · Combinatorial therapy · Motor neuron disease · Neurodegenerative disorders

Abbreviations

| ARX-2 | Actin-related protein 2 |
|-------|------------------------|
| BCAA | Branched-chain amino acid |
| Bcat2 | BCAA transaminase 2 |
| ETC | Electron transport chain |
| HIF | Hypoxia-inducible factor |
| 4-HNE | 4-Hydroxynonenal |
| hnRNP | Heterogeneous nuclear ribonucleoprotein |
| IMM | Inner mitochondrial membrane |
| MFN2 | Mitofusin 2 |
| MMP | Mitochondrial membrane potential |
| mtDNA | Mitochondrial DNA |
| NAIP | Neuronal apoptosis inhibitory protein (or NLR family apoptosis inhibitor protein) |
| NCALD | Neurocalcin delta |
| OMM | Outer mitochondrial membrane |
| PGAM5 | PGAM family member 5 |
| PGK1 | Phosphoglycerate kinase 1 |
| ROS | Reactive oxygen species |
| SMA | Spinal muscular atrophy |
| SMN | Survival motor neuron |
| TIM | Translocase of the inner membrane |
| TOM | Translocase of the outer membrane |
| tRNA | Transfer RNA |
| UBA1 | Ubiquitin-like modifier activating enzyme 1 |
| VDAC1 | Voltage-dependent anion-selective channel 1 |
| Vps13D | Vacuolar protein sorting 13 homolog D |

Introduction
Spinal muscular atrophy (SMA) is a monogenetic motor neuron disease on the verge of being redefined, largely due to notable therapeutic breakthroughs over the last decade. SMA is caused by mutations in the survival motor neuron 1 (SMN1) gene, leading to loss of its SMN protein product [1] (Fig. 1a). Due to a complex, highly repeated DNA sequence, the human genome contains an inverted duplication in the SMN region of chromosome 5, producing the near-identical duplicate gene, SMN2. A single nucleotide polymorphism in exon 7 of SMN2 leads to removal of exon 7 in 80–90% of transcripts; this truncated transcript is unstable and quickly...
degraded [2, 3]. SMN2 is therefore unable to compensate for mutated SMN1 leading to suboptimal levels of SMN protein. Humans have variable copy numbers of the SMN2 gene (again due to the repeating nature of this region of chromosome 5), and increased copy numbers of SMN2 can partially compensate for SMN1 mutation. This is reflected in time of onset and severity of symptoms in patients [4].

Patients have traditionally been grouped into sub-types of SMA with disease severity and motor milestones influenced by SMN2 copy number [5] (Fig. 1a). Type 0 patients have one copy of SMN2, with prenatal motor weakness, paralysis, and death weeks after birth. Type 1 patients are more common, with two copies of SMN2 and obvious motor symptoms within the first few months of life as they do not develop head control. Untreated, Type 1 patients have a life expectancy of around 2 years. Patients with three copies of SMN2 are characterised as Type 2, with symptom onset between 6 months and 2 years and development of motor skills such as sitting and possibly standing. Type 3 patients develop motor symptoms after 18 months old, have three or four copies of SMN2, and are likely to reach the motor milestone of unassisted walking and have a normal lifespan [6]. These SMA patient sub-types are based on the natural history of the disease. However, we have reached a new therapeutic era for SMA, with the approval and licencing of three genetic therapies: Spinraza® is an antisense oligonucleotide that modulates splicing of SMN2 to increase SMN production [7]; Zolgensma® is a viral vector that introduces a second copy of SMN1 to boost SMN expression [8]; and Evrysdi® is a small molecule that also alters SMN2 splicing [9]. Treatment with any one of these therapies significantly extends the time to invasive respiratory ventilation and life expectancy for many patients with SMA (most trials to date have been conducted in Type 1 patients). However, emerging evidence from patients treated with these “SMN-replacement” therapies reveals an ongoing loss of function and continued presence of neuromuscular symptoms [10]. Children treated earlier, before motor symptoms develop, have the highest chance of achieving successive motor milestones, while children who are treated at a later disease time point continue to be at high risk of needing supported ventilation [11] and enteral feeding [12]. The effect of these therapies in adults with Types 2/3 SMA is even less clear, not least because of the heterogeneity of clinical symptoms and small
patient group sizes. Nevertheless, there is some evidence of stabilisation or even improvement in motor symptoms in adult patients [13]. Thus, there is a growing body of evidence indicating that replacing SMN protein levels in patients can only go part-way to relieving symptoms due to affected tissues being too far down the degeneration pathway [14]. SMN-independent therapies are therefore needed to act in concert with SMN-replacement and further benefit patients with SMA (e.g., “SMN + therapies” [15]).

As a multi-systemic disorder, SMA affects many cell types since SMN protein is ubiquitously expressed throughout the body [16]. Undoubtedly though, motor neurons and muscle cells are a predominant site of cellular pathology. Neurons and muscle cells are in turn two of the most energy-dependent cells within the body; therefore, as mitochondria are primarily known for their role in energy and metabolic pathways, it is not hard to envision their involvement in SMA based upon this role. Yet mitochondria are no longer viewed solely as the ‘powerhouse’ of the cell and are implicated in many other aspects of cellular function that intersect with the aetiology of SMA and known roles of the SMN protein. Initially, SMN protein was reported to function in transcriptional processes but is now known to also play roles in protein translation and related proteostatic mechanisms such as autophagy and ubiquitination [17]. Dissecting these varied functions of SMN across a disease of heterogenous expression has been made possible through the development of animal models of varying severity (e.g., severe, intermediate, and mild mouse models, reflecting Types 1, 2, and 3/4 in patients, respectively) [18, 19]. By providing an overview of the mitochondrial dysfunction in SMA, our intention is to guide molecular mechanistic understanding and aid translational targeting of mitochondria, which offer many routes for complementary therapeutic interventions to current SMN-replacement therapies.

**Mitochondrial dysfunction in SMA**

**Mitochondrial respiration and oxidative phosphorylation**

Mitochondrial respiration refers to the set of metabolic reactions and processes that require oxygen to generate ATP. Of this process, oxidative phosphorylation mediated via the electron transport chain (ETC; complexes I–V) is the final step. Unsurprisingly, energetic disturbances suggestive of underlying mitochondrial dysfunction are present in muscle biopsies from patients with SMA (Table 1). Overall, SMA muscle pathology is associated with a decrease in mitochondrial respiration, reduced activity in oxidative phosphorylation enzymes, and a concomitant reduction in expression of both nuclear-encoded and mitochondrial-encoded subunits of the oxidative phosphorylation machinery [20–24]. This energetic disturbance has since been corroborated in various animal and cell culture models [25–31]. Interestingly, SMA patient-derived myoblasts and differentiated myotubes showed an intrinsic energy deficit characterised by increased reliance on mitochondrial ATP production [29], that may be borne out in patients with Type 3 SMA [32]. Taken together, these studies reveal a deficit in oxidative phosphorylation activity in tissue and cells relevant to SMA pathology. Moreover, these deficits are evident across the clinical spectrum of SMA and are not solely a feature of the more severe (i.e., Type 1) phenotype.

**Reactive oxygen species and oxidative stress**

As by-products of oxidative phosphorylation, as well as other mitochondrial and cellular biochemical reactions, reactive oxygen species (ROS) is an umbrella term for a group of molecular species. ROS are well-known for their pathological role in oxidative processes and resultant oxidative stress, but also play a physiological role in cell signalling and homeostasis [33]. Although neither ROS production nor oxidative stress are exclusively mitochondrial functions, both are underpinned by mitochondria and are a classic example of the double-edged role that mitochondria often play in cellular life. Based upon the oxidative phosphorylation defects in SMA, it follows that there is also evidence of altered ROS levels and oxidative stress in post-mortem patient material [34] and models of SMA [25, 26, 30, 35–37] (Table 2). Overall, the main finding has been of increased ROS and oxidative stress in SMA pathology, with any exceptions indicating that tissue/cell-type differences and the type of ROS examined are important. Relevantly, 4-hydroxy-nonenal (4-HNE) is generated primarily within mitochondria and is a marker of lipid peroxidation [38]. Although not exhaustively examined, 4-HNE is the only oxidative stress marker so far that has been associated with motor neuron pathology [27, 34, 35].

Mechanistically, SMN1 and SMN2 splicing [39–41] and activity of the SMN complex [42] can be regulated by ROS in oxidative stress-inducing conditions (Table 2). This suggests that increased ROS may be pathological in SMA through disruption of physiological ROS functions. Concurrently, oxidative stress induced by paraquat (a compound that increases mitochondrial ROS production [43]) reduces SMN protein levels [40, 41]. Therefore, along with reduced levels of SMN protein due to SMN mutation, increased mitochondrial ROS production may exacerbate and further reduce SMN protein levels. Whether reduced SMN levels in patients with SMA directly affects mitochondrial ROS-generating processes as shown in cell studies [26, 36, 37], or whether mitochondrial ROS production and oxidative stress are increased due to an external factor (that may also...
| SMA type/model                                                                 | Respiration rate | Cellular ATP levels | Enzyme activity | Enzyme                                    | Transcript expression | Transcripts          | Protein expression | Proteins | References |
|--------------------------------------------------------------------------------|-----------------|--------------------|------------------|-------------------------------------------|-----------------------|---------------------|-------------------|----------|------------|
| Patient skeletal muscle fibres: vastus lateralis of quadriceps (SMA type unknown; mean age 5.8 years) | Reduced          |                    | Reduced          | Complex I; II–III; IV; PDHC; citrate synthase |                       |                     |                   |          | [20]       |
| Patient skeletal muscle (Types 1–3)                                             | Reduced          |                    | Reduced          | Complex II; IV; citrate synthase           |                       |                     |                   |          |            |
| Patient muscle (muscle group and SMA type unknown; mean age 3.1 years)          | Reduced          |                    | Reduced          | Complex I; II; III; I–III; II–III; IV; V; citrate synthase |                       |                     |                   |          | [22]       |
| Patient quadriceps femorals muscle (Types 1 and 3)                              | Reduced          |                    | Reduced (Type 1) | NDUFB1; CYC1; SL25A4                       |                       |                     |                   |          |            |
| Patient quadriceps/paraspinal muscle (Types 1–3)                                | Reduced          |                    | Reduced          | Complex I; II–III; IV; citrate synthase   | Reduced (myo-blasts) | MT-ND1; SDHA; MT-CO1; MT-CO2; COX4I1; MT-ATP6 | Reduced         |          |            |
| Patient-derived iPSC-MNs/astrocytes                                             | No change (astrocytes) |                |                  |                                           |                       |                     |                   |          | [27]       |
| Type 1 patient-derived myoblasts/myotubes                                       | Reduced (myo-blasts) |                |                  |                                           |                       |                     |                   |          | [29]       |
| Spinal cord from Taiwanese mice (P5, P8)                                         | Reduced          |                    |                  |                                           |                       |                     | Reduced         |          | [28]       |
| Heart from Taiwanese mice (P1)                                                  | Reduced          |                    |                  |                                           |                       |                     | Increased       |          | [30]       |
| Spinal MNs from Hung–Li SMA mice (P9)                                            | Reduced          |                    |                  |                                           |                       |                     | Reduced         |          | [26]       |
| Cultured MNs from SMNA7 mice (E12.5)                                             | Reduced          |                    |                  |                                           |                       |                     | Reduced         |          |            |
be SMA-related) is not yet clear. To address this question, it is pertinent to consider other aspects of SMA pathology that may be involved in producing an oxidative environment, specifically, the involvement of hypoxia.

Mitochondria are the main oxygen consumers of the cell and are critically dependent on oxygen availability for mediating their canonical function of oxidative phosphorylation. Consequently, they are implicitly involved in oxygen-sensing, and in turn, hypoxic cellular pathways, which interlinks with their role in intermediary metabolism [44]. Hypoxic changes are present in neuronal and non-neuronal tissues of SMA model mice at an early symptomatic time point [45, 46]. Like oxidative stress, hypoxia is mechanistically associated with SMN2 splicing, promoting exon 7 skipping through heterogeneous nuclear ribonucleoprotein (hnRNP)-A1 (a negative regulatory splicing factor of SMN2 exon 7) in a severe mouse model of SMA [47]. Therapeutically, hnRNPA1 binding is blocked by Spinraza®, which promotes exon 7 inclusion and production of full-length SMN protein [15]. Hypoxic pathways are also triggered at the molecular level by ROS production and hypoxia-inducible factors (HIFs), an oxygen-regulated family of transcription factors that modify glycolytic capacity and are reported sensors of mitochondrial health [48]. Under normal oxygen conditions, HIF1α protein is rapidly degraded by ubiquitination processes involving the SMN-relevant proteins, ubiquitin-like modifier activating enzyme 1 (UBA1) [49, 50] and ubiquitin carboxyl-terminal hydrolase L1 [51, 52]. During hypoxia, increased mitochondrial ROS stabilises HIF1α protein, leading to further activation of hypoxic signalling pathways. Due to functional changes in SMN-related ubiquitination, basal degradation of HIF1α may be altered in SMA with increased mitochondrial ROS production further exacerbating this process. These potential hypoxic interactions between SMN and mitochondria have not been fully explored. Yet hypoxia offers a feasible environmental factor for influencing development of SMA, and unarguably, is a modifying influence on mitochondrial function.

**Mitochondrial metabolism**

Mitochondria are integral to metabolic pathways, both in terms of using end products as sources of electrons for the electron transport chain and providing ATP for further metabolic processes. Metabolism in turn is a critical link between molecular pathology and clinical care, since changes in nutritional care of patients can have direct impacts on metabolic function and vice versa. Metabolic dysfunction is an understudied area of research in SMA, but few studies have investigated this have found distinct perturbations in various kinds of metabolism across patient groups. Glucose, amino acids, and lipids can all be metabolised to provide substrates for ATP generation in mitochondria.

---

**Table 1** (continued)

| SMA type/model | Respiration rate | Cellular ATP levels | Protein expression | Enzyme activity | Transcript expression | Proteins |
|---------------|-----------------|--------------------|-------------------|----------------|---------------------|----------|
| Flexor tibialis and extensor plantaris (fast-twitch) and extensor soleus (slow-twitch) muscles from Smn∆7/∆7; huSMN2+/+micec | Reduced (fast-twitch) | No change | Complex I: IV; citrate synthase | Reduced (fast-twitch) | No change | NDUFB8; SDHB; UQCRCC2; COX1; ATP5A |
| Smn morphant zebrafish embryos | Reduced | Reduced | ATP5A | [28] |

All five complexes of the oxidative phosphorylation system show alterations in enzyme activity. Expression changes are found in transcripts and proteins encoded by both the nuclear and mitochondrial (denoted by ‘MT-’) genomes across all five complexes: MT-ND1, NDUFB1, and NDUFB8 (complex I); SDHA and SDHB (complex II); CYC1 and UQCRC2 (complex III); MT-CO1, MT-CO2, COX4, and COX4I1 (complex IV); ATP-5A, and MT-ATP6, and SLC25A4 (complex V). Mouse models of SMA are defined as severe, intermediate, or mild (reflecting SMA Types 1, 2, and 3/4, respectively). iPSC induced pluripotent stem cell, MNs motor neurons, PDHC pyruvate dehydrogenase complex, SMA spinal muscular atrophy. **References** [31, 28, 15, 47, 49, 50, 51, 52].

---

**Notes:**

- Bold text indicates significant changes.
- Italics indicate increased activity.
- Underline indicates decreased activity.
- Italicized text indicates significant changes.
Glucose metabolism is dysregulated in both patients and models of SMA. Mild and intermediate mouse models of SMA show glucose intolerance that increases with age as well as hyperglycaemia, increased insulin sensitivity, and fasting hyperglycaemia [54, 55]. These metabolic phenotypes are accompanied by morphological changes in the pancreas, with pancreatic islet cells showing an increased proportion of glucagon-producing cells (α cells) and a decreased proportion of insulin-producing cells (β cells). This change in islet cell composition was also found in patients with Type 1 SMA [54]. Patients with SMA are reported to have increased visceral fat mass, and children with Type 2 SMA and obesity are at higher risk for insulin resistance [56].

There is also evidence of amino acid metabolism dysregulation, again in both clinical and pre-clinical SMA research. Branched-chain amino acid (BCAA) pathways showed major changes in expression at early and symptomatic time points in a severe SMA mouse model, notably with reduced BCAA transaminase 2 (Bcat2) expression as a major catabolic enzyme of BCAAs [57]. This dysregulation of amino acid metabolism was also found in patients with Type 2 SMA [56]. Dyslipidemia and fatty deposits were found in the liver post-mortem in a cohort of patients with Type 2 SMA, which is mimicked in an intermediate mouse model [58]. This study also reported global dysregulation of fat and lipid metabolism. In the era of SMN-replacement therapies, these secondary characteristics of SMA are likely to become more pressing, both in terms of combinatorial therapy development and long-term disease management. At the cellular level, the ability to effectively switch between energetic fuels in response to fluctuating environmental conditions (such as during development or neuronal signalling) is dependent on the inherent metabolic flexibility of mitochondria,
which is mediated by their ability to change shape [59, 60]. Whether dysregulation in all three mitochondrial fuels in SMA pathology reflects loss of this adaptive ability in mitochondria remains to be determined.

Apoptosis

SMA pathology is primarily defined by motor neuron loss in the spinal cord, which reasonably may occur through apoptosis as a cell fate mechanism. Mitochondria are well-known as key activators of the intrinsic pathway of apoptosis [61], which involves a combination of pro- and anti-apoptotic proteins, including Bcl-2 family members, caspase family members, cytochrome C, and p53. In support of a role for apoptosis in SMA, several studies have shown altered levels of these proteins in patients and models of SMA [62]. Further involvement of SMN protein at the molecular level can be inferred through SMN interactions with known apoptotic proteins. Recombinant SMN directly interacts with the anti-apoptotic and outer mitochondrial membrane (OMM) protein, Bcl-2, to exert a synergistic effect against apoptosis in cell culture studies [63, 64]. Although the physiological significance of this interaction has not been confirmed [65], there is ample evidence implicating Bcl-2 and other family members across the spectrum of SMA pathology in patient tissue [66], animal models [67], and cell culture models [68, 69]. Another SMN interaction of interest to apoptosis is the pro-apoptotic protein, p53, which in turn regulates the Bcl-2 family of proteins [70]. P53 is a transcription factor involved in cell stress and can both induce apoptosis (nuclear p53) and repress autophagy (cytosolic p53), which in part is dependent on p53 translocation to external (OMM) and internal (matrix) mitochondrial locations [71]. Nuclear p53 activity is selectively upregulated in disease-vulnerable spinal motor neurons in an intermediate mouse model of SMA [72], while direct interaction between SMN and nuclear p53 correlates with SMA disease severity in patient-derived fibroblasts [73]. Zinc-finger protein 1 (ZPR1) is another apoptosis-inducing protein and SMN interactor [74, 75]. ZPR1 expression levels are reduced in patients with SMA and may play a role in disease severity [76]. Corroboratively, ZPR1 was identified as a potential modifier of SMA pathology in mild and severe mouse models of SMA, with alternating effects on apoptosis that are dependent on ZPR1 expression levels [77]. Finally, the gene for neuronal apoptosis inhibitory protein (or NLR family apoptosis inhibitor protein; NAIP) is located within the genomic region of chromosome 5 that encompasses SMN1. NAIP is not the causative gene for SMA but NAIP mutations are suggested to modify disease severity in patients with SMA [78, 79], albeit their clinical significance is unclear [4]. Nevertheless, as NAIP is regulated by release of caspases 3 and 9 during apoptosis [80], it is reasonable that NAIP may play a modifying role in apoptosis of SMA motor neurons [81, 82]. Aside from apoptosis, NAIP is most studied for its role in another mitochondrial pathway, that of activation of the innate immune system [83]. Thus, clarifying the mitochondrial role of Bcl-2, p53, ZPR1, and NAIP in apoptosis may shed further light on cell death mechanisms in SMN disease-vulnerable motor neurons.

Mitochondrial trafficking

Mitochondria constantly move around the cell to meet local metabolic and energetic demands, and are trafficked along the cellular cytoskeleton [84]. Cytoskeletal and trafficking processes have previously been implicated in SMA [17], suggesting that reasonably, SMN may also play a role in mitochondrial trafficking. Accordingly, smn-1 was identified from a genetic screen in C. elegans to detect components of abnormal mitochondrial localisation [85]. Through interactions with actin-related protein 2 (ARX-2), smn-1 was subsequently shown to influence mitochondrial localisation and distribution in muscle myofilaments. Patient-derived cell culture models of SMA show motor neuron-specific reductions in mitochondrial movement along axons [26, 86, 87] (Table 3). Reduced mitochondrial trafficking in SMA cell models may therefore reflect dissociation of SMN interactions between ARX-2 and actin filaments. Alternatively, tubulin-related mitochondrial trafficking is commonly implicated in other forms of SMA [88, 89] and motor neuron diseases [90], while intermediate filament aggregation disrupts mitochondrial movement in giant axonal neuropathy, a related neurological disorder [91]. Determining whether these cytoskeletal alterations in mitochondrial trafficking across disease classifications share SMN-related molecular disturbances may enable utilisation of shared modelling and therapeutic approaches.

Mitochondrial quality control mechanisms

Mitochondrial dynamics

Overlapping with a role in mitochondrial trafficking, the cytoskeleton is also involved in mitochondrial dynamics, which describes the intertwined fission and fusion capabilities of mitochondria [92]. Mitochondrial fission is a means of both mitochondrial replication and removal of damaged or dysfunctional mitochondria (i.e., mitophagy). Mitochondrial fusion enables the exchange of metabolites and other molecules (including mitochondrial DNA [mtDNA]) among mitochondria and leads to generation of the interconnected mitochondrial networks that are present in many cell types, such as neurons and muscle. Related to mitochondrial dynamics are mitochondrial biogenesis (generation of new mitochondria from pre-existing mitochondria) and
## Table 3 Mitochondrial abnormalities in spinal muscular atrophy

| SMA type/model                                      | Trafficking | Distribution | mtDNA content | Number | MMP | Morphology | Size          | Rescue      | References |
|-----------------------------------------------------|-------------|--------------|---------------|--------|-----|------------|---------------|-------------|------------|
| Patient skeletal muscle (Types 1–3)                 | Reduced     |              |               |        |     |            |               |             | [21]       |
| Patient quadriceps/paraspinal muscle (Types 1–3)    | Reduced     |              |               |        |     |            |               |             | [24]       |
| Type 1 patient-derived MNs from iPSCs/hESCs         | Reduced     | Reduced      | Reduced       | Reduced|     | Reduced    |                | N-Acetyl-cysteine (antioxidant) | [86]       |
| Type 1 patient-derived iPSC-MNs                     | Reduced     | Reduced      | Reduced       | Reduced|     | Reduced    |                | Z-FA-FMK (protease inhibitor)   | [87]       |
| Type 1 patient-derived myoblasts/myotubes          | No change   |              |               |        |     |            |               |             | [29]       |
| Smn siRNA knockdown in NSC-34 cells                 |             |              |               |        |     |            |               | Increased   | [25]       |
| Diaphragm from SMNΔ7 mice (P14)b                     |              |              |               |        |     | Reduced    |                | Reduced (presynaptic)          | [95]       |
| Tibialis anterior muscle from SMNΔ7 mice (P13)b     | Reduced     | Normal       | Reduced       | Normal |     |            |                | (presynaptic)  | [97]       |
| Tibialis anterior muscle from SMNΔ7 mice (P14)b     | Normal      | Reduced      | Reduced       | Normal |     | Degenerative | Swollen       | [105]       |
| Cardiomyocytes from SMNΔ7 mice (P14)b               |             |              |               |        |     |            |                |             |            |
mitophagy [93]. Taken together, these interrelated functions are viewed as quality control mechanisms to maintain a healthy mitochondrial population and optimise the energetic and metabolic output of the cell. Mitochondrial dynamics have already been implicated in the pathogenesis of neurodegenerative diseases [94], but have not yet become an area of active research for SMA. Despite this, there are indications that mitochondrial dynamics may be disrupted in smn-1 mutant worms, with disruption of the typical elongated mitochondrial network in the belly wall muscle [85]. This phenotype is supported by SMA cell models [26, 86, 87] showing reduced mitochondrial length, a concomitant increase in fragmentation, and reductions in fusion transcripts (Table 3). Overall, these changes are suggestive of impaired mitochondrial fusion in SMA.

| SMA type/model | Trafficking Distribution | mtDNA content | Number | MMP | Morphology | Size | Rescue | References |
|----------------|--------------------------|----------------|--------|-----|------------|------|--------|------------|
| Spinal cord (P3, P9) and cultured MNs (E12.5) from SMNΔ7 mice | Reduced | Reduced | Fragmented/abnormal | Reduced | [26] |
| Diaphragm/soleus from Taiwanese mice (P4) | Fragmented/abnormal (diaphragm) | Reduced | Normal | Normal | [106] |
| Intercostal muscles from Taiwanese mice (P4) | Normal | Normal | [108] |
| Cervical spinal cord from Taiwanese mice (P3) | Abnormal | Reduced | [107] |
| Tibialis anterior muscle from SMN2B mice (P21) | In vacuoles | | | | [103] |
| C. elegans smn-1 mutant body wall muscle | Abnormal | Abnormal | | | [85] |

Mouse models of SMA are defined as severe, intermediate, or mild (reflecting SMA Types 1, 2, and 3/4, respectively). hESCs human embryonic stem cells, iPSCs induced pluripotent stem cell, MMP mitochondrial membrane potential, MNs motor neurons, mtDNA mitochondrial DNA, SMA spinal muscular atrophy, SMN survival motor neuron

Mitochondrial biogenesis and mitophagy

Mitochondrial biogenesis can be inferred through regulation of relevant transcriptional pathways, or more directly shown by the amount of mtDNA and/or number of mitochondria. There is evidence that all of these processes are altered in SMA pathology [21, 24, 26, 86, 87, 95–97]. In particular, reduced mtDNA content has been reported in patient muscle tissue [21, 24] that partially tracks with the clinical phenotype [23]. Reduced mitochondrial number and/or density are found in mouse [95–97] and cell culture [86, 87] models of SMA (Table 3). Importantly, there are muscle-specific differences that correlate with the disease phenotype: fewer mitochondria are detected in the disease-vulnerable tibialis anterior muscle of a severe SMA mouse model [96, 97], while no change was reported in the diaphragm at a similar postnatal stage [95]. Together these findings suggest there
are less mitochondria in pathologically relevant cell types. However, it is not known how reduction of SMN protein and function is involved. Interestingly, there are clinical reports of mitochondrial phenocopies of SMA [98], defined as a disease that phenotypically resembles SMN-associated SMA but without SMN1 gene mutations. These phenocopies also show mtDNA depletion [99–102] and may prove useful for mechanistic understanding of the relationship between mtDNA content and SMA development.

Due to the reduced energetic capability of mitochondria in SMA, mitophagy should be activated as a cellular response to remove dysfunctional mitochondria. Vacuoles containing mitochondria were reported in an intermediate mouse model of SMA, and not in control mice [103], suggesting that mitophagy is activated in SMA. Mitophagy can be indirectly inferred by depolarisation of the mitochondrial membrane potential (MMP), which reflects the functional status and viability of mitochondria [104]. This has been examined in cell models of SMA [25, 26, 86] (Table 3), with stable knockdown of SMN levels associated with a depolarised MMP. This suggests that the mitochondrial population is functionally suboptimal and a mitophagic response should be induced. Further investigation of this process is needed to determine how altered SMN autophagic function may be involved, possibly preventing efficient removal of dysfunctional mitochondria.

**Mitochondrial morphology and size**

Mitochondrial morphology and size are remarkably heterogeneous among cell types and are regulated in part by mitochondrial dynamics and the cytoskeleton. Together they impact upon the mitochondrion’s energetic and metabolic output. Morphological abnormalities of mitochondria are evident in animal models of SMA [26, 85, 105–107] (Table 3), including alterations in cristae (the mitochondrial location of the ETC) at a pre-symptomatic stage of disease [26]. In addition, both larger [105, 106, 108] and smaller [26, 95, 107] mitochondria have been reported in animal models of SMA (Table 3). Swollen or enlarged mitochondria may represent degenerative mechanisms acting downstream of reduced SMN protein levels. While smaller mitochondria may reflect a physiological phenotype of SMA pathology: indeed smaller mitochondria are associated with reduced SMN levels in cell culture models of SMA [86, 87].

**Mitochondrial import of proteins**

Due to the small number of proteins encoded by the mitochondrial genome (13 of >1000 mitochondrial proteins in humans [109]), mitochondria must import the rest of the proteins and other macromolecules needed for its function from the cytosol. Import occurs through protein complexes located within the outer and inner mitochondrial membranes, namely translocases of the outer membrane (TOM) and inner membrane (TIM) [110]. Mitochondrial import has not been directly investigated in SMA research, but there is tentative evidence that this process could be affected by SMA pathology. Reduced expression of mitochondrial import proteins has been shown in patient muscle biopsies [24] and patient-derived spinal motor neurons [111], albeit not in a mild mouse model of SMA [31]. Further, voltage-dependent anion-selective channel 1 (VDAC1) is an OMM import protein that interacts with stasimon, a protein involved in synaptic transmission and already implicated in SMN pathways [112]. VDAC1–stasimon interactions occur at specialised endoplasmic reticulum (ER)–mitochondria membrane contact sites [113]. Functionality of the VDAC1–stasimon interaction may be affected by reduced SMN levels, thereby implicating mitochondrial protein import in SMA pathology. Then rather curiously, recombinant SMN protein was shown to interact with TIM50 [114], a component of the TIM23 complex in the IMM that facilitates protein import from the TOM complex [115]. Within the TIM23 complex, TIM50 is the main receptor for inner membrane and matrix-bound proteins and is closely linked to ETC assembly. The physiological relevance of this interaction has not been examined further. Although it may be expected that cytoplasmic SMN interacts with mitochondrial TIM50 before mitochondrial import, putative localisation of SMN at the IMM in rat spinal cord [116] hints at the possibility that SMN may directly interact with TIM50 in mitochondria. These potential SMN–mitochondrial connections in protein import need further corroboration to enable understanding of their functional significance.

**SMN localisation at mitochondria**

The prevailing viewpoint in the SMA field is that SMN does not localise to mitochondria [25, 117, 118]. However, re-evaluation of these studies suggests that there may be alternative interpretations of these conclusions. For example, although electron microscopy studies are technically challenging and their interpretation can be problematic, mitochondrial localisation of SMN in endogenous, disease-free rat spinal cord at multiple developmental stages was reported by Pagliardini et al. [116]. SMN was most convincingly detected in close apposition to the OMM, a location corroborated by colocalisation of SMN and ARX-2 at mitochondria in *C. elegans* [85]. Surprisingly, SMN was also reported at the IMM. Additional support for mitochondrial localisation of SMN, particularly at the OMM, can be gleaned from protein interactions: either directly through putative SMN interactions with mitochondrial proteins...
Revisiting the role of mitochondria in spinal muscular atrophy

(Bcl-2, p53, and TIM50) or indirectly via SMN-interacting proteins that also localise to mitochondria, namely, ARX-2, stasimon, and neurocalcin delta (NCALD) [119], albeit most of these interactions have not been directly examined in this context. Transient localisation of SMN to mitochondria under certain cellular conditions and/or developmental stages seems likely. Given its function in transcription, translation, and proteostatic mechanisms, SMN is well suited to play a role in mitochondrial function. That mitochondria have recently been proposed as hubs of cellular proteostasis [120, 121] suggests this interaction could be reciprocal.

A mitochondria-focused model of SMA disease and treatment

The role of mitochondria in SMA

Mitochondrial dysfunction has long been reported in patients with SMA. Unsurprisingly, mitochondrial energetic and metabolic alterations are associated with reduction of SMN protein and SMA pathology (Fig. 2). By combining current research, a model of mitochondrial dysfunction in SMA can be postulated that incorporates overlapping SMN functions (Fig. 3). Alterations in mitochondrial quality control mechanisms will lead to less efficient removal and reduced production of new mitochondria. Linking mitochondrial biogenesis and mitophagy to SMN-related function, β-catenin functions through the developmental Wnt signalling pathway [122] and was identified along with disrupted ubiquitin homeostasis as a driver of disease pathogenesis in SMA [50]. The cytosolic form of the mitochondrial phosphatase, PGAM family member 5 (PGAM5), was recently identified as a novel activator of Wnt/β-catenin signalling, stimulating mitochondrial biogenesis and increasing mitochondrial number in response to mitochondrial stress [123]. In addition, the mitochondrial form of PGAM5 acts as a repressor of Wnt/β-catenin signalling and is involved in mitophagy [125, 126], again during times of mitochondrial stress. Opposing functions for related protein isoforms in the same signalling pathway suggests that Wnt/β-catenin signalling, and in turn SMN, may be important to mitochondrial turnover.

Altered mitochondrial quality control and trafficking/cytoskeletal defects may lead to changes in mitochondrial morphology, size, and subcellular distribution. Further mechanistic insights can again be inferred from known SMN-interacting proteins: HuD is an RNA-binding protein and SMN interactor [127], and together, both proteins influence mRNA transport [128]. Concurrently, HuD plays a role in mitochondrial dynamics, promoting mitochondrial fusion via transport of mitofusin 2 (MFN2) mRNA in

![Fig. 2](image)

**Fig. 2** Energetic and metabolic changes in spinal muscular atrophy. Decreased activity in the electron transport chain (ETC) is found in patients with spinal muscular atrophy (SMA) and across models of SMA. This leads to a decrease in ATP and increased reactive oxygen species (ROS) production. ETC dysfunction may be linked to the metabolic dysregulation evident in SMA. Increased ROS production can modulate survival motor neuron (SMN) splicing as well as the SMN complex itself. Increased ROS causes oxidative stress, which is linked to an increase in 4-hydroxynoneal (4HNE) in SMA motor neurons. Hypoxia is another pathological process in SMA that also influences mitochondrial function, leading to an increase in production of hypoxic inducible factors (HIFs). In addition, HIF1α is modulated by ROS through ubiquitination processes involving SMN-relevant proteins, leading to activation of downstream hypoxic pathways. Hypoxia is also associated with an increase in SMN splicing factors, namely, heterogeneous nuclear ribonucleoprotein (hnRNP)-A1/A2.
mouse pancreatic β-cells [129], a known site of metabolic dysfunction in SMA. MFN2 is an OMM protein that is essential for mitochondrial fusion, and also a causative gene for Charcot–Marie–Tooth disease [94]. Whether reduction of SMN levels in SMA motor neurons can affect HuD–MFN2 transport is not known but warrants further investigation, especially given that mitochondrial fusion appears impaired in SMA models. SMN also plays a well-described role in ubiquitin homeostasis with the ubiquitin protein, UBA1, a known SMN interactor that is already implicated in SMA pathology [130]. Of relevance here, this SMN-related pathway was recently linked to mitochondrial size mechanisms in Drosophila [131]. Specifically, vacuolar protein sorting 13 homolog D (Vps13D) was identified from a screen investigating ubiquitin and UBA1-mediated autophagy mechanisms during intestinal development. Vps13D was subsequently shown to play a role in mediating mitochondrial size through fission and fusion mechanisms. Potential overlapping of SMN and UBA1/ubiquitin function in this mitochondrial size
pathway provides another point at which mitochondrial and SMN functions may intersect.

Mitochondrial structure is known to beget its function. Consequently, abnormalities in mitochondrial morphology and dynamics may be reflected in patients with SMA by reduced energetic capability at the cellular level and dysregulated metabolic control at the systems-wide level. Apoptosis should be inevitable but imbalances in SMN-related proteins (e.g., p53, Bcl-2 family) may hinder this process. Hypoxia could be an early influence on mitochondrial dysfunction, leading to increased mitochondrial ROS production and oxidative stress. Recently, hnRNPA1 (the SMN2 splicing factor regulated by hypoxia) was shown to interact with a specific subset of mitochondrial transfer RNAs (tRNAs) [132] that were unexpectedly detected in the cytoplasm of HeLa cells. These proteins are typically found in the mitochondrial matrix where they are involved in translation of mitochondrial proteins. The biological significance of these cytosolic mitochondrial tRNAs is not yet apparent. They may be released following mitophagy and/or form part of regulatory crosstalk between mitochondria and the nucleus, possibly in times of mitochondrial stress. Further supporting this potential link between SMN2 splicing and mitochondrial function, another hnRN protein, hnRNPA2, also binds to SMN2 exon 7 and alters SMN2 protein levels [133]. HnRNPA2 is an established transcriptional co-activator involved in mediating the nuclear response to mitochondrial stress, at least in mouse skeletal muscle cells [134]. Theoretically then, SMN2 splicing may be altered by hnRN proteins in response to mitochondrial stress resulting from hypoxia. Notably, the pattern of mitochondrial dysfunction described is not unique to SMA and is akin to that reported for other neurodegenerative diseases [135, 136]. However, layered throughout this model is the potential for involvement of SMN function, not least its roles in ubiquitination and autophagy. Understanding this underlying mitochondrial deficit and how it intersects with SMN function could benefit patients with SMA at all stages of disease. In this regard, it is also pertinent to ask whether insight into SMA disease mechanisms can be obtained from present understanding of mitochondria.

Mitochondria are unequivocally bioenergetic and biosynthetic organelles, yet current research suggests that they should not be viewed solely as such. Indeed, mitochondria are increasingly recognised as signalling hubs either through generation of second messengers (e.g., ROS, Ca\(^{2+}\), ATP and other metabolites) or by acting as scaffolds for signalling complexes that form on the OMM [137–139]. Likely linked to their signalling capacity, is the emerging role that mitochondria play in cell fate pathways aside from apoptosis, including the cell cycle [140–142] and cellular differentiation [143, 144]. Mitochondrial involvement in these cell fate pathways highlights an interplay between ROS signalling and mitochondrial dynamics, both of which are altered in SMA pathology. Indeed, effective execution of these cell fate roles is likely to be affected by a functionally suboptimal mitochondrial population. Future consideration of SMN function in mitochondrial signalling and cell fate pathways may reveal a role for mitochondria in SMA that lies outside their canonical energetic role.

**Mitochondria-targeted therapies for SMA**

The primary treatment aimed at targeting mitochondria in SMA is Olesoxime, which made it through to phase III clinical trials. Olesoxime exerts its neuroprotective effects by modulating the mitochondrial permeability transition pore (an opening between the inner and outer mitochondrial membranes that is induced during pathology [145]), increasing cell survival in multiple in vitro and in vivo models [146]. Phase II clinical trials in non-ambulatory patients with Types 2/3 SMA showed a stabilisation, or even a slight increase, in motor function over the study period, whilst patients receiving a placebo showed a decline in motor function [147]. Unfortunately, Roche announced in 2018 that they were cancelling the phase III clinical trial due to difficulties in production and dosage as well as disappointing long-term results (https://www.treatsma.uk/wp-content/uploads/2018/05/2018-05-30-Olesoxime-PG-update-May-2018.pdf). However, since it is now clear that additional therapies are needed in combination with SMN replacement, cancelling Olesoxime clinical trials may come to be seen as premature and could still offer an option as a combinatorial (“SMN+”) therapy.

Targeting metabolic pathways is a second strategy that could benefit mitochondrial function in SMA. For example, targeting the glycolytic enzyme, phosphoglycerate kinase 1 (PGK1), either genetically or pharmacologically, can improve motor neuron health in SMA models [28]. Transcriptionally PGK1 is induced by HIF1α [148] and targeted to mitochondria following hypoxia [149], therefore the therapeutic benefit of PGK1 may involve hypoxic SMA mechanisms. Likewise, treatment with prednisolone (a corticosteroid that targets the transcription factor that modulates BCAA metabolism) or genetic overexpression of this corticosteroid that targets the transcription factor that modulates mitochondrial metabolism and therefore boosting of this metabolic pathway, doubled the lifespan of an intermediate mouse model of SMA. Glucocorticoids themselves are synthesised in mitochondria [150]. Potentially the therapeutic effects of prednisolone may also tap into mitochondrial-related glucocorticoid pathways.

More general metabolic approaches include changes to diet and exercise. In a mild SMA mouse model, forced exercise improved various markers of SMA pathology including fatigability and motor neuron survival [151]. Further, a functional decrease in mitochondrial oxidative capacity
was reversed by exercise intervention in a subset of muscle fibres in the same mouse model [31]. However, whether these results can be directly translated to human patients remains to be determined. A systematic review of evidence for and against exercise in patients with SMA was inconclusive due to heterogeneity of the patient groups and exercise performed [152]. This is obviously a difficult therapy to apply to patients with SMA due to their decreased motor abilities. A simpler target may be food intake. Targeting lipid dysregulation in SMA mice with a low-fat diet doubled their survival [58], whilst BCAA supplementation also improved SMA mouse model lifespan [57]. A recent systematic review described the lack of evidence for nutritional care in patients with SMA, an issue that is likely to become more pressing now that patients are living longer [153].

The early success of Olesoxime indicates that targeting mitochondria may still be an exciting avenue for future therapy development as a systemic, combinatorial option. Several therapies are being tested in other neurodegenerative diseases with mitochondrial dysfunction as a pathogenic hallmark, including metformin [154] and resveratrol [155] (see also recent reviews of mitochondrial therapies [156, 157]). Photobiomodulation is an alternative non-pharmacological approach that is gaining traction in neurodegenerative and brain injury fields [158, 159]. Photobiomodulation uses light energy to modulate biological function with reported mitochondrial effects including increased mitochondrial respiration and mtDNA levels [160], altered mitochondrial dynamics [161], increased MMP and ATP production [162, 163], and redox effects [164]. Given the demographic of the patient group, this is obviously an attractive strategy since it is non-invasive, has minimal side effects, and enables targeted, localised treatment. Of relevance to SMA, positive effects of photobiomodulation have been reported on muscle fatigue in healthy subjects [165], while there are indications of efficacy in models of Alzheimer’s disease, with improvements in both behavioural and molecular phenotypes [166]. Mitochondrial transplantation is another potential new avenue in mitochondrial therapies [167, 168], with the caveat that it is still very much at the experimental stage [169, 170]. This approach is based on the premise of transplanting entire mitochondria to treat disease tissue [171]. It has recently been shown that neurons can take up mitochondria from neighbouring astrocytes in stroke models [172], and this mechanism may be boosted by administering mesenchymal stem cells [173]. Given that multiple mitochondrial functions are disrupted in SMA, targeting mitochondria at the organelle level is appealing. These therapeutic approaches are yet to be tested in SMA models but highlight future research opportunities.

Conclusions

As the genetic cause of SMA, SMN is imperative to disentangling the molecular phenotype of SMA and translating it back to the clinic. Yet determining the role of mitochondria in SMN function and SMA pathology may lead to clinical benefit that can complement SMN-replacement therapies. Mitochondria indisputably play an energetic role in motor neurons and muscle. Nevertheless, understanding of mitochondrial function has evolved considerably to show their more embedded role in wider cellular life. Intersection between SMN function and mitochondria can occur at multiple stages of SMA pathology. In turn, both SMN protein and mitochondria show pathological applicability that extends outside of motor neurons and muscle cells to affect every organ of the body. As SMA moves into a new era of treatment and disease progression, understanding the myriad roles of SMN protein and how they impact on generic and cell-type specific functions is ever more crucial for realisation of a cure for SMA.

Funding RJ holds a Daphne Jackson Trust Fellowship funded by Medical Research Scotland. HC is funded by the My Name’5 Doddie foundation (Project Grant) and LML by a Medical Research Council (MRC) studentship (Precision Medicine PhD Studentship).

Availability of data and material Not applicable.

Code availability Not applicable.

Declarations

Conflict of interest/competing interest THG has served on SMA advisory boards for Roche.

Ethics approval (include appropriate approvals or waivers) Not applicable.

Consent to participate Not applicable.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
1. Lefebvre S, Bürglen L, Reboullet S et al (1995) Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–165. https://doi.org/10.1016/0092-8674(95)90460-3

2. Lorson CL, Hahnen E, Androphy EJ, Wirth B (1999) A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci USA 96:6307–6311. https://doi.org/10.1073/pnas.96.11.6307

3. Monani UR, Lorson CL, Parsons DW et al (1999) A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 8:1177–1183. https://doi.org/10.1093/hmg/8.7.1177

4. Wadman RI, Jansen MD, Stam M et al (2020) Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy. Brain Commun 2:ffca075. https://doi.org/10.1093/Braincomms/fcca075

5. Talbot K, Tizzano EF (2017) The clinical landscape for SMA in a new therapeutic era. Gene Ther 24:529–533. https://doi.org/10.1038/gt.2017.52

6. Serra-Juèc C, Tizzano EF (2019) Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors. Eur J Hum Genet 27:1774–1782. https://doi.org/10.1038/s41431-019-0415-4

7. Finkel RS, Mercuri E, Darras BT et al (2017) Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med 377:1723–1732. https://doi.org/10.1056/NEJMoa1702752

8. Mendell JR, Al-Zaidey S, Shell R et al (2017) Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med 377:1713–1722. https://doi.org/10.1056/NEJMoa1706198

9. Ratui H, Ebeling M, Baird J et al (2018) Discovery of risdiplam, a selective survival of motor neuron-2 (SMN2) gene splicing modifier for the treatment of spinal muscular atrophy (SMA). J Med Chem 61:6501–6517. https://doi.org/10.1021/acs.jmedchem.8b00741

10. Darrow JJ, Sharma M, Shroff M, Wagner AK (2020) Efficacy and costs of spinal muscular atrophy drugs. Sci Transl Med 12:eaay9648. https://doi.org/10.1126/scitranslmed.aay9648

11. Sansone VA, Pirola A, Albamonte E et al (2020) Respiratory needs in patients with type 1 spinal muscular atrophy treated with Nusinersen. J Pediatr 219:223-228.e4. https://doi.org/10.1016/j.jpeds.2019.12.047

12. Hully M, Barrieras C,Chabalier D et al (2020) Palliative care in SMA type 1: a prospective multicenter French study based on parents’ reports. Front Pediatr 8:4. https://doi.org/10.3389/fped.2020.00004

13. Hagenacker T, Wurster CD, Günther R et al (2020) Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional multicentre, observational cohort study. Lancet Neurol 19:317–325. https://doi.org/10.1016/S1474-4422(20)30037-5

14. Hensel N, Kubinski S, Claus P (2020) The need for SMN-independent treatments of spinal muscular atrophy (SMA) to complement SMN-enhancing drugs. Front Neurol 11:45. https://doi.org/10.3389/fneur.2020.00045

15. Groen EJN, Talbot K, Gillingwater TH (2018) Advances in therapy for spinal muscular atrophy: promises and challenges. Nat Rev Neurol 14:214–224. https://doi.org/10.1038/nrneurol.2018.4

16. Groen EJN, Perenthaler E, Courtney NL et al (2018) Temporal and tissue-specific variability of SMN protein levels in mouse models of spinal muscular atrophy. Hum Mol Genet 27:2851–2862. https://doi.org/10.1093/hmg/ddy195

17. Chaytow H, Huang YT, Gillingwater TH, Fuller KME (2018) The role of survival motor neuron protein (SMN) in protein homeostasis. Cell Mol Life Sci 75:3877–3894. https://doi.org/10.1007/s00018-018-2849-1

18. Edens BM, Ajour-Driess S, Ma L, Ma YC (2015) Molecular mechanisms and animal models of spinal muscular atrophy. Biochim Biophys Acta Mol Basis Dis 1852:685–692. https://doi.org/10.1016/j.bbadis.2014.07.024

19. Sleigh JN, Gillingwater TH, Talbot K (2011) The contribution of mouse models to understanding the pathogenesis of spinal muscular atrophy. Dis Model Mech 4:457–467. https://doi.org/10.1242/dmm.007245

20. Sperli W, Skladal D, Gnaiger E et al (1997) High resolution respirometry of permeabilized skeletal muscle fibers in the diagnosis of neuromuscular disorders. Mol Cell Biochem 174:71–78. https://doi.org/10.1016/S0300-9884(95)00680-5

21. Berger A, Mayr JA, Meierhofer D et al (2003) Severe depletion of mitochondrial DNA in spinal muscular atrophy. Acta Neuropathol 105:245–251. https://doi.org/10.1007/s00401-002-0638-1

22. Jongpiputvanich S, Sueblinvong T, Norapucsonton T (2005) Mitochondrial respiratory chain dysfunction in various neuromuscular diseases. J Clin Neurosci 12:426–428. https://doi.org/10.1016/j.jocn.2004.06.014

23. Millino C, Fanin M, Vettori A et al (2009) Different atrophy-hypertrophy transcription pathways in muscles affected by severe and mild spinal muscular atrophy. BMC Med 7:14. https://doi.org/10.1186/1741-7015-7-14

24. Ripolone M, Ronchi D, Violano R et al (2015) Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy. JAMA Neurol 72:666–675. https://doi.org/10.1001/jamaneuro.2015.0178

25. Acasdi G, Lee I, Li X et al (2009) Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy. J Neurosci Res 87:2748–2756. https://doi.org/10.1002/jnr.22106

26. Miller N, Shi H, Zelikovich AS, Ma YC (2015) Motor neuron mitochondrial dysfunction in spinal muscular atrophy. Hum Mol Genet 25:3395–3406. https://doi.org/10.1093/hmg/ddw262

27. Patitucci TN, Ebert AD (2016) SMN deficiency does not induce oxidative stress in SMA iPSC-derived astrocytes or motor neurons. Hum Mol Genet 25:514–523. https://doi.org/10.1093/hmg/ddv489

28. Boyd PJ, Tu WY, Sharrock HK et al (2017) Bioenergetic status modulates motor neuron vulnerability and pathogenesis in a zebrafish model of spinal muscular atrophy. PLoS Genet 13:e1006744. https://doi.org/10.1371/journal.pgen.1006744

29. Hellbach N, Peterson S, Haehnke D et al (2018) Impaired myogenic development, differentiation and function in hESC-derived SMA myoblasts and myotubes. PLoS ONE 13:e0205589. https://doi.org/10.1371/journal.pone.0205589

30. Maxwell GK, Szunyogová E, Sharrock HK et al (2018) Developmental and degenerative cardiac defects in the Taiwanese mouse model of severe spinal muscular atrophy. J Anat 232:965–978. https://doi.org/10.1111/joa.12793

31. Houdéine L, D’Amico D, Bastin J et al (2019) Low-intensity running and high-intensity swimming exercises differentially improve energy metabolism in mice with mild spinal muscular atrophy. Front Physiol 10:1258. https://doi.org/10.3389/fphys.2019.01258

32. Montes J, Garber CE, Kramer SS et al (2015) Single-blind, randomised, controlled clinical trial of exercise in ambulatory spinal muscular atrophy: why are the results negative? J Neuromuscul Dis 2:463–470. https://doi.org/10.3323/JND-150101

33. Sies H, Jones DP (2020) Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol 21:363–383. https://doi.org/10.1038/s41580-020-0230-3
34. Hayashi M, Araki S, Arai N et al (2002) Oxidative stress and disturbed glutamate transport in spinal muscular atrophy. Brain Dev 24:770–775. https://doi.org/10.1016/S0387-7604(02)00103-1
35. Shababi M, Habibi J, Ma L et al (2012) Partial restoration of cardiac-vascular defects in a rescued severe model of spinal muscular atrophy. J Mol Cell Cardiol 52:1074–1082. https://doi.org/10.1016/j.yjmcc.2012.01.005
36. Wang ZB, Zhang X, Li XJ (2013) Recapitulation of spinal motor neuron-specific disease phenotypes in a human cell model of spinal muscular atrophy. Cell Res 23:378–393. https://doi.org/10.1038/cr.2012.166
37. Ando S, Funato M, Ohuchi K et al (2017) Edaravone is a candidate agent for spinal muscular atrophy: In vitro analysis using a human induced pluripotent stem cells-derived disease model. Eur J Pharmacol 814:161–168. https://doi.org/10.1016/j.ejphar.2017.08.005
38. Zhong H, Yin H (2015) Role of lipid peroxidation derived 4-hydroxynonenal (4-HNE) in cancer: focusing on mitochondria. Redox Biol 4:193–199. https://doi.org/10.1016/j.redox.2014.12.011
39. Maracchioni A, Totaro A, Angelini DF et al (2007) Mitochondrial damage modulates alternative splicing in neuronal cells: implications for neurodegeneration. J Neurochem 100:142–153. https://doi.org/10.1111/j.1471-4159.2006.04204.x
40. Singh NN, Seo J, Rahn SJ, Singh RN (2012) A multi-exon-skipping detection assay reveals surprising diversity of splice isoforms of spinal muscular atrophy genes. PLoS ONE 7:e49595. https://doi.org/10.1371/journal.pone.0049595
41. Seo J, Singh NN, Ottesen EW et al (2016) Oxidative stress triggers body-wide skipping of multiple exons of the spinal muscular atrophy gene. PLoS ONE 11:e0154390. https://doi.org/10.1371/journal.pone.0154390
42. Lan W, Ottinger E, Cho S, Dreyfuss G (2008) Inactivation of the SMN complex by oxidative stress. Mol Cell 31:244–254. https://doi.org/10.1016/j.molcel.2008.06.004
43. Castello PR, Dreachsl DA, Patel M (2007) Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. J Biol Chem 282:14186–14193. https://doi.org/10.1074/jbc.M700827200
44. Fuhrmann DC, Briune B (2017) Mitochondrial composition and function under the control of hypoxia. Redox Biol 12:208–215. https://doi.org/10.1016/j.redox.2017.02.012
45. Somers E, Lees RD, Hoban K et al (2016) Vascular defects and spinal cord hypoxia in spinal muscular atrophy. Ann Neuroul 79:217–230. https://doi.org/10.1038/ana.2014.59
46. Hernandez-Gerez E, Dall’Angelo S, Collinson JM et al (2020) Widespread tissue hypoxia dysregulates cell and metabolic pathways in SMA. Ann Clin Transl Neuroul 7:1580–1593. https://doi.org/10.1002/acn2.51134
47. Bebee TW, Dominguez CE, Samadzadeh-tarighat S et al (2012) Hypoxia is a modulator of SMN2 splicing and disease severity in a severe SMA mouse model. Hum Mol Genet 21:4301–4313. https://doi.org/10.1038/hmg.dsd263
48. Thomas LW, Ashcroft M (2019) Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. Cell Mol Life Sci 76:1759–1777. https://doi.org/10.1007/s00018-019-03039-y
49. Kamura T, Sato S, Iwai K et al (2000) Activation of HIF1 ubiquitination by a reconstituted von Hippel–Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA 35:e142. https://doi.org/10.1038/sj.ncomms7932
50. Wishart TM, Mutsaers CA, Riessland M et al (2014) Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. J Clin Investig 124:1821–1834. https://doi.org/10.1172/JCI71318
51. Goto Y, Zeng L, Yeom CJ et al (2015) UCHL1 provides diagnostic and antimetastatic strategies due to its deubiquitinating effect on HIF-1α. Nat Commun 6:6153. https://doi.org/10.1038/ncomms7153
52. Hsu SH, Lai MC, Er TK et al (2010) Ubiquitin carboxyl-terminal hydrolase L1 (UCHL1) regulates the level of SMN expression through ubiquitination in primary spinal muscular atrophy fibroblasts. Clin Chim Acta 411:1920–1928. https://doi.org/10.1016/j.cca.2010.07.035
53. Spinelli JB, Haigis MC (2018) The multifaceted contributions of mitochondria to cellular metabolism. Nat Cell Biol 20:745–754. https://doi.org/10.1038/s41556-018-0124-1
54. Bowerman M, Swoboda KJ, Michalski JP et al (2012) Glucose metabolism and pancreatic defects in spinal muscular atrophy. Ann Neuroul 72:256–268. https://doi.org/10.1002/ana.23582
55. Bowerman M, Michalski JP, Beauvais A et al (2014) Defects in pancreatic development and glucose metabolism in SMN-depleted mice independent of canonical spinal muscular atrophy neuromuscular pathology. Hum Mol Genet 23:3432–3444. https://doi.org/10.1093/hmg/ddu052
56. Davis RH, Miller EA, Zhang RZ, Swoboda KJ (2015) Response to fasting and glucose loading in a cohort of well children with spinal muscular atrophy type II. J Pediatr 167:1362–1368.e1. https://doi.org/10.1016/j.jpeds.2015.09.023
57. Walter LM, Deguise MO, Meijboom KE et al (2018) Interventions targeting glucocorticoid-Krüppel-like factor 15-branched-chain amino acid signalling improve disease phenotypes in spinal muscular atrophy mice. EBioMedicine 31:226–242. https://doi.org/10.1016/j.ebiom.2018.04.024
58. Deguise MO, Baranello G, Mastella C et al (2019) Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. Ann Clin Transl Neuroul 6:1519–1532. https://doi.org/10.1002/acn3.50855
59. Muoio DM (2014) Metabolic inflexibility: when mitochondrial incoordination leads to metabolic gridlock. Cell 159:1253–1262. https://doi.org/10.1016/j.cell.2014.11.034
60. Smith RL, Soeters MR, Wüst RC, Houtkooper RH (2018) Metabolic flexibility as an energy resource and requirements in health and disease. Endocrin Rev 39:489–517. https://doi.org/10.1210/er.2017-00211
61. Xiong S, Mu T, Wang G, Jiang X (2014) Mitochondria-mediated apoptosis in mammals. Protein Cell 5:737–749. https://doi.org/10.1007/s13238-014-0089-1
62. Anderton RS, Meloni BP, Mastaglia FL, Boulos S (2013) Spinal muscular atrophy and the anti-apoptotic role of survival of motor neuron (SMN) protein. Mol Neurobiol 47:821–832. https://doi.org/10.1007/s12035-013-8399-5
63. Iwahashi H, Eguchi Y, Yasuhara N et al (1997) Synergistic anti-apoptotic activity between Bcl-2 and SMN implicated in spinal muscular atrophy. Nature 390:413–417. https://doi.org/10.1038/37144
64. Sato K, Eguchi Y, Kodama TS, Tsujimoto Y (2000) Regions essential for the interaction between Bcl-2 and SMN, the spinal muscular atrophy disease gene product. Cell Death Differ 7:374–383. https://doi.org/10.1038/sj.cdd.4400660
65. Coovvert DD, Le TF, Morris GE et al (2000) Does the survival motor neuron protein (SMN) interact with Bcl-2? J Med Genet 37:536–539
66. Simic G, Sesko-Simic D, Lucassen PJ et al (2000) Ultrastructural analysis and TUNEL demonstrate motor neuron apoptosis in Werdnig–Hoffmann disease. J Neuropathol Exp Neuroul 59:398–407. https://doi.org/10.1093/jnen/59.5.398
67. Piras A, Schiaffino L, Boido M et al (2017) Inhibition of autophagy delays motoneuron degeneration and extends lifespan in a mouse model of spinal muscular atrophy. Cell Death Dis 8:3223–3238. https://doi.org/10.1038/s41419-017-0086-4
68. Tsai LK, Tsai MS, Ting CH, Li H (2008) Multiple therapeutic effects of valproic acid in spinal muscular atrophy model mice. J Mol Med 86:1243–1254. https://doi.org/10.1007/s00109-008-0388-1

69. Garcia A, Mincheva S, Gou-Fabregas M et al (2011) A new model to study spinal muscular atrophy: neurite degeneration and cell death is counteracted by BCL-XL overexpression in motor-neurons. Neurobiol Dis 42:415–426. https://doi.org/10.1016/j.nbd.2011.02.003

70. Green DR, Kroemer G (2009) Cytoplasmic functions of the nbd. 2011. 02. 003

71. Márinho G, Niso-Santano M, Baehrecke EH, Kroemer G (2014) Self-consuming: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 15:81–94. https://doi.org/10.1038/nrm3735

72. Simon CM, Dai Y, Van Alstyne M et al (2017) Converging mechanisms of p53 activation drive motor neuron degeneration in spinal muscular atrophy. Cell Rep 21:3767–3780. https://doi.org/10.1016/j.celrep.2017.12.003

73. Young PJ, Day PM, Zhou J et al (2002) A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy. J Biol Chem 277:2852–2859. https://doi.org/10.1074/jbc.M108769200

74. Gangwani L, Mikrut M, Theroux S et al (2001) Spinal muscular atrophy disrupts the interaction of ZPR1 with the SMN protein. Nat Cell Biol 3:376–383. https://doi.org/10.1038/35070059

75. Gangwani L, Flavell RA, Davis RJ (2005) ZPR1 is essential for survival and is required for localization of the survival motor neurons (SMN) protein to Cajal bodies. Mol Cell Biol 25:2744–2756. https://doi.org/10.1128/mcb.25.7.2744-2756.2005

76. Helmkens C, Hofmann Y, Schoenen F et al (2003) Evidence for a modifying pathway in SMA discordant families: reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Hum Genet 114:11–21. https://doi.org/10.1007/s00439-003-1025-2

77. Ahmad S, Wang Y, Shaik GM et al (2012) The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy. Hum Mol Genet 21:2745–2758. https://doi.org/10.1093/hmg/dds102

78. Roy N, Mahadevan MS, McLean M et al (1995) The gene for neuronal apoptosis inhibitor protein is partially deleted in individuals with spinal muscular atrophy. Cell 80:167–178. https://doi.org/10.1016/0092-8674(95)00461-1

79. Soler-Bojicja C, Ferrer I, Alvarez JL et al (2003) Downregulation of Bcl-2 proteins in type I spinal muscular atrophy motor neurons during fetal development. J Neuropathol Exp Neurol 62:420–426. https://doi.org/10.1093/jnen/62.4.420

80. Liston P, Fong WG, Korneluk RG (2003) The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22:8568–8580. https://doi.org/10.1038/sj.onc.1207101

81. Tsai CH, Jong YJ, Hu CJ et al (2001) Molecular analysis of SMN, NIMP-R1 and P44 genes of SMA patients and their families. J Neurosci Res 190:35–40. https://doi.org/10.1002/0161-6434(2001)007:5<35::AID-JNR2>3.0.CO;2-0

82. Watahayati MS, Fatemeh H, Marini M et al (2009) Combination of SMN2 copy number and NAIAP deletion predicts disease severity in spinal muscular atrophy. Brain Dev 31:42–45. https://doi.org/10.1016/j.braindev.2008.08.012

83. Koford EM, Vance RE (2012) NAIPs: building an innate immune barrier against bacterial pathogens: NAIPs function as sensors that initiate innate immunity by detection of bacterial proteins in the host cell cytosol. BioEssays 34:589–598. https://doi.org/10.1002/bies.201200013

84. Cardanho-Ramos C, Faria-Pereira A, Morais VA (2020) Orchestrating mitochondria in neurons: cytoskeleton as the conductor. Cytoskeleton 77:65–75. https://doi.org/10.1002/cm.21585

85. Schultz J, Lee SJ, Cole T et al (2017) The secreted MSP domain of C. elegans VAPB homolog VPR-1 patterns the adult striated muscle mitochondrial reticulum via SMN-1. J Cell Sci 130:2175–2186. https://doi.org/10.1242/dev.152025

86. Xu CC, Denton KR, Wang ZB et al (2016) Abnormal mitochondrial transport and morphology as early pathological changes in human models of spinal muscular atrophy. DMM Dis Model Mech 9:39–49. https://doi.org/10.1242/dmm.021766

87. Wang Y, Xu C, Ma L et al (2019) Drug screening with human SMN2 reporter identifies SMN protein stabilizers to correct SMA pathology. Life Sci Alliance 2:e021800268. https://doi.org/10.26508/lsa.201800268

88. Hoang HT, Schlager MA, Carter AP, Bullock SL (2017) DYNC1H1 mutations associated with neurological diseases compromise processivity of dynein-dynactin-cargo adaptor complexes. Proc Natl Acad Sci USA 114:E1597–E1606. https://doi.org/10.1073/pnas.1620141114

89. Carrera LAM, Gabriel E, Donohoe CD et al (2018) Novel insights into SMALED2: BICD2 mutations increase microtubule stability and cause defects in axonal and NMJ development. Hum Mol Genet 27:1772–1784. https://doi.org/10.1093/hmg/ddy086

90. Lipka J, Kuijpers M, Jaworski J, Hoogenraad CC (2013) Mutations in cytoplasmic dynein and its regulators cause malformations of corticidal development and neurodegenerative diseases. Biochem Soc Trans 41:1605–1612. https://doi.org/10.1042/BST20130188

91. Israeli E, Dryanovski DI, Schumacker PT et al (2016) Intermediate filament aggregates cause mitochondrial dysmotility and increase energy demands in giant axonal neuropathy. Hum Mol Genet 25:2143–2157. https://doi.org/10.1093/hmg/ddw081

92. Detmer SA, Chan DC (2007) Functions and dysfunctions of mitochondrial dynamics. Nat Rev Mol Cell Biol 8:870–879. https://doi.org/10.1038/nrm2275

93. Picca A, Mankowski RT, Burman JL et al (2018) Mitochondrial quality control mechanisms as molecular targets in cardiac ageing. Nat Rev Cardiol 15:543–554. https://doi.org/10.1038/s41569-018-0059-z

94. Burté F, Carelli V, Chinnery PF, Yu-Wai-Man P (2015) Disrupted mitochondrial dynamics and neurodegenerative disorders. Nat Rev Neurol 11:11–24. https://doi.org/10.1038/nrneurol.2014.228

95. Kariya S, Park GH, Maeno-Hikichi Y et al (2008) Reduced SMN protein impairs maturation of the neuromuscular junctions in mouse models of spinal muscular atrophy. Hum Mol Genet 17:2552–2569. https://doi.org/10.1093/hmg/ddw156

96. Torres-Benito L, Neher MF, Cano R et al (2011) SMN requirement for synaptic vesicle, active zone and microtubule postnatal organization in motor nerve terminals. PLoS Os 6:e26164. https://doi.org/10.1371/journal.pone.0026164

97. Kong L, Wang X, Cho DW et al (2009) Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci 29:842–851. https://doi.org/10.1523/JNEUROSCI.4434-08.2009

98. Mancuso M, Filosto M, Hirano M, DiMauro S (2003) Spinal muscular atrophy and mitochondrial DNA depletion. Response to Barber et al. (2003) Acta Neuropathol 105:245–251. Acta Neuropathol 105:621–622. https://doi.org/10.1007/s00401-003-0699-9

99. Pons K, Andreetta F, Wang CH et al (1996) Mitochondrial myopathy simulating spinal muscular atrophy. Pediatr Neurol 15:153–158. https://doi.org/10.1016/0887-8994(96)00118-x

100. Rubio-Gozalbo M, Smeitink J, Ruitenbeek W et al (1999) Spinal muscular atrophy disrupts the interaction of ZPR1 with the SMN protein. Cytoskeleton 77:65–75. https://doi.org/10.1002/cm.21585

101. Mancuso M, Salvati L, Sacconi S et al (2002) Mitochondrial DNA depletion mutations in thymidine kinase gene with myopathy and SMA. Neurology 59:1197–1202. https://doi.org/10.1212/01.wnl.59.2.383
102. Boczonadi V, King MS, Smith AC et al (2018) Mitochondrial oxidoscerboxylylate carrier deficiency is associated with mitochondrial DNA depletion and spinul muscular atrophy—like disease. Genet Med 20:1224–1235. https://doi.org/10.1038/gim.2017.251

103. Deguise MO, Boyer JG, McFall ER et al (2016) Differential induction of muscle atrophy pathways in two mouse models of spinul muscular atrophy. Sci Rep 6:28846. https://doi.org/10.1038/srep28846

104. Zorova LD, Popkov VA, Plotnikov EY et al (2018) Mitochondrial membrane potential. Anal Biochem 552:50–59. https://doi.org/10.1016/j.ab.2017.07.009

105. Bevan AK, Huchinson KR, Foust KD et al (2010) Early heart failure in the SMNΔ7 model of spinal muscular atrophy and correction by postnatal scAAV9-SMN delivery. Hum Mol Genet 19:3895–3905. https://doi.org/10.1093/hmg/ddq300

106. Voigt T, Meyer K, Baum O, Schümperli D (2010) Ultrastructural changes in diaphragm neuromuscular junctions in a severe mouse model for Spinul Muscular Atrophy and their prevention by bifunctional U7 snRNA correcting SMN2 splicing. Neuro- muscul Disord 20:744–752. https://doi.org/10.1016/j.nmd.2010.06.010

107. Neve A, Trüb J, Saxena S, Schümperli D (2016) Central and peripheral defects in motor units of the diaphragm of spinul muscular atrophy mice. Mol Cell Neurosci 70:30–41. https://doi.org/10.1007/s11064-015-0077-3

108. Calvo SE, Mootha VK (2010) The mitochondrial proteome and human disease. Ann Rev Genom Hum Genet 11:25–44. https://doi.org/10.1146/annurev-genom-082509-141720

109. Chacinska A, Koehler CM, Milenkovic D et al (2009) Importing mitochondrial proteins: machineries and mechanisms. Cell 138:628–644. https://doi.org/10.1016/j.cell.2009.08.005

110. Ando S, Funato M, Ohuchi K et al (2019) The protective effects of Levetiracetam on a human iPSCs-derived spinal muscular atrophy model. Neurochem Res 44:1773–1779. https://doi.org/10.1007/s11064-019-02814-4

111. Lotti F, Imlach WL, Saieva L et al (2012) An SMN-dependent U12 splicing event essential for motor circuit function. Cell 151:440–454. https://doi.org/10.1016/j.cell.2012.09.012

112. Van Alstyne M, Lotti F, Dal Mas A et al (2018) Stasimon/Tmem41b localizes to mitochondria-associated ER membranes and is essential for mouse embryonic development. Biochem Biophys Res Commun 506:463–470. https://doi.org/10.1016/j. brc.2018.10.073

113. Xu H, Somers ZB, Robinson ML, Hebert MD (2005) Tim50a, a nuclear isoform of the mitochondrial Tim50, interacts with proteins involved in snRNP biogenesis. BMC Cell Biol 6:29. https://doi.org/10.1186/1471-2121-6-29

114. Callegari S, Cruz-Zaragoza LD, Rehling P, Rehling P (2020) From TOM to the TIM23 complex—handing over of a precursor. J Neurosci 37:11559–11571. https://doi.org/10.1523/JNEUROSCI.1528-17.2017

115. Rauschenberger V, Bernkopf DB, Krenn S et al (2017) The phosphatase Pgam5 antagonizes Wnt/β-catenin signalling in embryonic anterior-posterior axis patterning. Development 144:2234–2247. https://doi.org/10.1242/dev.144477

116. Chen G, Han Z, Feng D et al (2014) A regulatory signalling loop comprising the PGAM5 phosphatase and CK2 controls receptor-mediated mitophagy. Mol Cell 54:362–377. https://doi.org/10.1016/j.molcel.2014.02.034

117. Wu H, Xue D, Chen G et al (2014) The BCL2L1 and PGAM5 axis defines hypoxia-induced receptor-mediated mitophagy. Autophagy 10:1712–1725. https://doi.org/10.4161/auto.29568

118. Hubers L, Valderrama-Carvajal J, Laframboise J et al (2011) HuD interacts with survival motor neuron protein and can rescue spinal muscular atrophy-like neuronal defects. Hum Mol Genet 20:553–579. https://doi.org/10.1093/hmg/ddq500

119. Le Hao T, Duy PQ, An M et al (2017) HuD and the survival motor neuron protein interact in motoneurons and are essential for motoneuron development, function, and mRNA regulation. J Neurosci 37:11559–11571. https://doi.org/10.1523/JNEUR OSCIL.1528-17.2017

120. Callea S, Cruz-Zaragoza LD, Rehling P, Rehling P (2020) Axis defines hypoxia-induced receptor-mediated mitophagy. Cell Death Differ 27:1633–1643. https://doi.org/10.1038/s41418-019-0447-x

121. Green EJN, Gillingwater TH (2015) UBA1: at the crossroads of ubiquitin homeostasis and neurodegeneration. Trends Mol Med 21:622–632. https://doi.org/10.1016/j.molmed.2015.08.003

122. Anding AL, Wang C, Chang TK et al (2018) Vps13D encodes a ubiquitin-binding protein that is required for the regulation of mitochondrial size and clearance. Curr Biol 28:287–295. https://doi.org/10.1016/j.cub.2017.11.064

123. Jädy BE, Ketele A, Kiss T (2018) Dynamic association of human mRNP proteins with mitochondrial rRNAs in the cytosol. RNA 24:1706–1720. https://doi.org/10.1261/rna.066738.118

124. Hua Y, Vickers TA, Okunola HL et al (2008) Antisense masking of an hnRNP A1/A2 intronic splicing silencer corrects SMN2 splicing in transgenic mice. Am J Hum Genet 82:384–384. https://doi.org/10.1016/j.ajhg.2008.01.014

125. Guha M, Hua P, Fang JK, Avadhani NG (2009) Heterogeneous nuclear ribonucleoprotein A2 is a common transcriptional coactivator in the nuclear transcription response to mitochondrial respiratory stress. Mol Biol Cell 20:4107–4119. https://doi.org/10.1091/mc.09-04-0296
144. Iwata R, Casimir P, Vanderhaeghen P (2020) Mitochondrial
145. Pérez MJ, Quintanilla RA (2017) Development or disease: dual-
138. Mottis A, Herzig S, Auwerx J (2019) Mitocellular communica-
142. Han Y, Ishibashi S, Iglesias-Gonzalez J et al (2018) Ca²⁺-induced
141. Wang Z, Fan M, Candas D et al (2014) Cyclin B1/Cdk1 coordi-
139. Tan JX, Finkel T (2020) Mitochondria as intracellular signalling
135. Chen C, Turnbull DM, Reeve AK (2019) Mitochondrial dys-
146. Bordet T, Berna P, Abitbol JL, Pruss RM (2010) Olesoxime
153. Moore GE, Lindenmayer AW, McConchie GA et al (2016)
150. Picard M, McEwen BS, Epel ES, Sandi C (2018) An energetic
149. Li X, Jiang Y, Meisenhelder J et al (2016) Mitochondria-trans-
148. Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcrip-
152. Andrade S, Ramalho MJ, Pereira MDC, Loureiro JA (2018) Resveratrol brain delivery for neurological disorders prevention and treatment. Front Pharmacol 9:1261. https://doi.org/10.3389/fphar.2018.01261
154. Markowicz-Piasecka M, Sikora J, Szydlowska A et al (2017) Metformin—a future therapy for neurodegenerative diseases: theme: drug discovery, development and delivery in Alzheimer’s disease guest editor: Davide Brambilla. Pharm Res 34:2614–2627. https://doi.org/10.1007/s11095-017-2199-y
155. Andrade S, Ramalho MJ, Pereira MDC, Loureiro JA (2018) Resveratrol brain delivery for neurological disorders prevention and treatment. Front Pharmacol 9:1261. https://doi.org/10.3389/fphar.2018.01261
156. Murphy MP, Hartley RC (2018) Mitochondria as a therapeutic target for common pathologies, Nat Rev Drug Discov 17:865–886. https://doi.org/10.1038/nrd.2018.174
157. Weissig V (2020) Drug development for the therapy of mitochondrial diseases. Trends Mol Med 26:40–57. https://doi.org/10.1016/j.molmed.2019.09.002
158. Hong N (2019) Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends. Biomed Eng Lett 9:359–366. https://doi.org/10.1007/s13534-019-00115-x
159. Yang L, Youngblood H, Wu C, Zhang Q (2020) Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. Transl Neurodegener 9:19. https://doi.org/10.1186/s40035-020-00197-z
160. Serrage HJ, Joannisse S, Cooper PR et al (2019) Differential responses of myoblasts and myotubes to photobiomodulation are associated with mitochondrial number. J Biophotonics 12:e201800411. https://doi.org/10.1002/jbio.201800411
161. Wang R, Dong Y, Lu Y et al (2019) Photobiomodulation for global cerebral ischemia: targeting mitochondrial dynamics and functions. Mol Neurobiol 56:1852–1869. https://doi.org/10.1007/s12035-018-1191-9
162. Ferraresi C, Kaippper B, Avci P et al (2015) Low-level laser (light) therapy increases mitochondrial membrane potential and ATP synthesis in C2C12 myotubes with a peak response at 3–6 h. Photochem Photobiol 91:411–416. https://doi.org/10.1111/php.12397
163. Chang SY, Lee MY, Chung FS et al (2019) Enhanced mitochondrial membrane potential and ATP synthesis by photobiomodulation increases viability of the auditory cell line after gentamicin-induced intronic apoptosis. Sci Rep 9:19248. https://doi.org/10.1038/s41598-019-511-9
164. Hamblin MR (2018) Mechanisms and mitochondrial redox signalling in photobiomodulation. Photochem Photobiol 94:199–212. https://doi.org/10.1111/php.12864
165. Vanin AA, Verhagen E, Barboza SD et al (2018) Photobiomodulation therapy for the improvement of muscular performance and reduction of muscular fatigue associated with exercise in healthy people: a systematic review and meta-analysis. Lasers Med Sci 33:181–214. https://doi.org/10.1007/s10103-017-2368-6
166. Zhang Z, Shen Q, Wu X et al (2020) Activation of PKA/SIRT1 signalling pathway by photobiomodulation therapy reduces Aβ levels in Alzheimer’s disease models. Aging Cell 19:e13054. https://doi.org/10.1111/acel.13054
167. McCully JD, Levitsky S, del Nido PJ, Cowan DB (2016) Mitochondrial transplantation for therapeutic use. Clin Transl Med 5:16. https://doi.org/10.1186/s40169-016-0095-4
168. Golilhue JL, Rabchevsky AG (2017) Prospects for therapeutic mitochondrial transplantation. Mitochondrion 35:70–79. https://doi.org/10.1016/j.mito.2017.05.007
169. Bertero E, Maack C, O’Rourke B (2018) Mitochondrial transplantation in humans: “magical” cure or cause for concern? J Clin Investig 128:5191–5194. https://doi.org/10.1172/JCI124944
170. Lightowers RN, Chrzanowska-Lightowers ZM, Russell OM (2020) Mitochondrial transplantation—a possible therapeutic review. Neuromuscul Disord 26:395–404. https://doi.org/10.1016/j.nmd.2016.05.005
171. Markowicz-Piasecka M, Sikora J, Szydlowska A et al (2017) Metformin—a future therapy for neurodegenerative diseases: theme: drug discovery, development and delivery in Alzheimer’s disease guest editor: Davide Brambilla. Pharm Res 34:2614–2627. https://doi.org/10.1007/s11095-017-2199-y
172. Andrade S, Ramalho MJ, Pereira MDC, Loureiro JA (2018) Resveratrol brain delivery for neurological disorders prevention and treatment. Front Pharmacol 9:1261. https://doi.org/10.3389/fphar.2018.01261
173. Murphy MP, Hartley RC (2018) Mitochondria as a therapeutic target for common pathologies, Nat Rev Drug Discov 17:865–886. https://doi.org/10.1038/nrd.2018.174
174. Weissig V (2020) Drug development for the therapy of mitochondrial diseases. Trends Mol Med 26:40–57. https://doi.org/10.1016/j.molmed.2019.09.002
175. Hong N (2019) Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends. Biomed Eng Lett 9:359–366. https://doi.org/10.1007/s13534-019-00115-x
for mitochondrial dysfunction? EMBO Rep 21:e50964. https://doi.org/10.15252/embr.202050964

171. Rogers RS, Bhattacharya J (2013) When cells become organelle donors. Physiology 28:414–422. https://doi.org/10.1152/physiol.00032.2013

172. Hayakawa K, Esposito E, Wang X et al (2016) Transfer of mitochondria from astrocytes to neurons after stroke. Nature 535:551–555. https://doi.org/10.1038/nature18928

173. Babenko VA, Silachev DN, Zorova LD et al (2015) Improving the post-stroke therapeutic potency of mesenchymal multipotent stromal cells by cocultivation with cortical neurons: the role of crosstalk between cells. Stem Cells Transl Med 4:1011–1020. https://doi.org/10.5966/sctm.2015-0010

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.